918972-54-0Relevant articles and documents
Identification, synthesis and characterization of impurities of Montelukast sodium
Sunil Kumar,Anjaneyulu,Hima Bindu
, p. 4536 - 4546 (2012/02/04)
Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.
PROCESS FOR PREPARING MONTELUKAST SODIUM CONTAINING CONTROLLED LEVELS OF IMPURITIES
-
Page/Page column 9, (2008/12/07)
The present invention is directed to a process of preparing montelukast or a salt thereof with minimal amounts of impurities, such as a dehydration impurity (compound (VI)) or a cyclic ether impurity (compound (VIII)).
PREPARATION OF MONTELUKAST
-
Page/Page column 26, (2008/06/13)
A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying.